Kathyrn E Stephenson
Biographic Data
| ID | 6070528 |
|---|---|
| NAME | Kathyrn E Stephenson |
| GIVEN NAMES | Kathyrn E |
| FAMILY NAME | Stephenson |
| SIGNATURE | STEPHENSON K E |
| AFFILIATIONS | Bisola O. Ojikutu is with the Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. Kathyrn E. Stephenson is with the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Kenneth H. Mayer is with the Fenway Institute, Fenway Community Health Center, Boston, MA, and Harvard Medical School, Boston, MA. Karen M. Emmons is with the Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public... |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 6 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 1 |
Building Trust in Covid-19 Vaccines and Beyond Through Authentic Community Investment
COVID-19 vaccine development has advanced at lighting speed. Research that would normally require years has been completed in months. As a result of this unprecedented effort, two vaccine candidates, mRNA-1273 (Moderna, Cambridge, MA) and BNT162b2 (Pfizer, New York, NY), have been found to be safe and more than 90% effective in preventing symptomatic COVID-19 shortly after vaccination. These vaccines are extremely promising and will eventually be…
Building Trust in Covid-19 Vaccines and Beyond Through Authentic Community Investment
COVID-19 vaccine development has advanced at lighting speed. Research that would normally require years has been completed in months. As a result of this unprecedented effort, two vaccine candidates, mRNA-1273 (Moderna, Cambridge, MA) and BNT162b2 (Pfizer, New York, NY), have been found to be safe and more than 90% effective in preventing symptomatic COVID-19 shortly after vaccination. These vaccines are extremely promising and will eventually be…
Building Trust in Covid-19 Vaccines and Beyond Through Authentic Community Investment
COVID-19 vaccine development has advanced at lighting speed. Research that would normally require years has been completed in months. As a result of this unprecedented effort, two vaccine candidates, mRNA-1273 (Moderna, Cambridge, MA) and BNT162b2 (Pfizer, New York, NY), have been found to be safe and more than 90% effective in preventing symptomatic COVID-19 shortly after vaccination. These vaccines are extremely promising and will eventually be…
Business (1 work) · Community engagement (1 work) · Coronavirus disease 2019 (COVID-19) (1 work) · Economic growth (1 work) · Economics (1 work) · Government (linguistics) (1 work) · Indigenous (1 work) · Investment (military) (1 work) · Law (1 work) · Medicine (1 work)